Ⅲ_b及Ⅲ_c期结肠癌辅助化疗后行卡培他滨巩固化疗的临床研究

Clinical research of stage Ⅲ_b and Ⅲ_c colon cancer treating with Capecitabine as consolidation chemotherapy after adjuvant chemotherapy

目的研究一组Ⅲb及Ⅲc期结肠癌术后患者,在辅助化疗后继续行卡培他滨巩固化疗,观察对无病生存率的影响。方法对入组的2005年6月至2008年9月我院收治的22例Ⅲb及Ⅲc结肠癌术后患者,行常规6个月辅助化疗,休息3～6个月之后给予6个周期卡培他滨口服巩固化疗,观察无病生存率及巩固化疗期间的相关不良反应,无病生存率的计算采用Life Tables分析法。结果使用卡培他滨作为Ⅲb及Ⅲc期结肠癌术后巩固化疗十分安全,初步观察复发转移率较低,无病生存率较高,不良反应轻微。结论Ⅲb及Ⅲc结肠癌术后患者接受卡培他滨巩固化疗可能改善无病生存率,值得进一步行大规模的临床研究。

Abstract ： Objective To observe the DFS （ disease-free survival rate） of a group of postoperative stage m b and Ⅲc colon cancer patients, who continued to take oral Capecitabine as consolidation chemotherapy after adjuvant chemothera- py. Methods 22 postoperative stage Ⅲb and Ⅲc colon cancer patients treated in our hospital from June 2005 to Septem- ber 2008 were enrolled. After 3 - 6 months rest following 6-month routine adjuvant chemotherapy, they continued to take 6 cycles of oral Capecitabine as consolidation chemotherapy, then whose disease-free survival and related adverse effects dur- ing therapy were observed, DFS was calculated by Life Tables analysis. Results Using Capecitabine as consolidation chemotherapy in postoperative stage Ⅲ b and ⅢIc colon cancer patients is of high safety, with low recurrence and metastasis rates, and high disease-free survival rate, as the adverse effects are limited. Conclusion Postoperative Ⅲ b and Ⅲc colon cancer patients receive oral Capecitabine as consolidation chemotherapy may improve disease-free survival rate, suggesting it is worthy of further and extensive clinical studies.